Eli Lilly's Q1: Rally Potential, Targeting $1200

Eli Lillys Q1 results showcased impressive growth in weight-loss and diabetes meds, driving revenue up nearly 60% and sales over 100% YoY. Despite recent stock dips, analysts predict a bullish outlook, with a consensus price target of $1,215, representing a 26% upside. Valuation looks attractive as P/E ratio drops with soaring earnings, and profits tripled in three years. Eli Lillys fundamentals suggest a rally potential, poised to surpass $1,000 short-term and continue climbing for long-term holders. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3773410ccb862638